Cover Image

Efficacy and safety of apatinib versus sorafenib/placebo in first-line treatment for intermediate and advanced primary liver cancer: A systematic review and meta-analysis

Background: Apatinib is a novel tyrosine kinase inhibitor used in the treatment of advanced hepatocellular carcinoma (HCC). For decades, sorafenib has been a classic first-line treatment option for patients with HCC. This meta-analysis aimed to assess the efficacy and safety of apatinib versus soraf...

Full description

Saved in:

Bibliographic Details
Main Authors:	Dan Peng (Author), Yongqing Cai (Author), Geng Chen (Author), Min Hou (Author), Xiaofeng Luo (Author), Zhuoma Dongzhi (Author), Hongjun Xie (Author), Yao Liu (Author)
Format:	Book
Published:	Frontiers Media S.A., 2023-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis
by: Zhiwei Zheng, et al.
Published: (2024)

Apatinib for molecular targeted therapy in tumor
by: Zhang H
Published: (2015)

Case report: Long-term partial response of apatinib plus paclitaxel as second-line therapy in a patient with metastatic gastric cancer
by: Shengya Fu, et al.
Published: (2022)

Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
by: Yan Li, et al.
Published: (2022)

Improved drug targeting to liver tumor by sorafenib-loaded folate-decorated bovine serum albumin nanoparticles
by: Haipeng Wang, et al.
Published: (2019)

Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma
by: Koen G. A. M. Hussaarts, et al.
Published: (2021)

Efficacy and Safety of Apatinib in Patients with Recurrent Glioblastoma
by: Hao Lin, et al.
Published: (2023)

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
by: Ye Peng, et al.
Published: (2022)

Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option
by: Hong-Hong Zhang, et al.
Published: (2022)

Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats
by: Agnieszka Karbownik, et al.
Published: (2020)

Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression
by: Zhongyu Wang, et al.
Published: (2021)

Efficacy of the low dose apatinib plus deep hyperthermia as third-line or later treatment in HER-2 negative advanced gastric cancer
by: Guohu Han, et al.
Published: (2023)

Apatinib treatment is effective for metastatic malignant phyllodes tumors of the breast: a case report
by: Xiaolu Wang, et al.
Published: (2021)

Effect of X-ray radiation on the pharmacokinetics of apatinib in vivo in rats
by: Shi-Qi Dong, et al.
Published: (2022)

The Development of Lipid-Based Sorafenib Granules to Enhance the Oral Absorption of Sorafenib
by: Jaylen C. Mans, et al.
Published: (2023)

Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer
by: Zhongmian Pan, et al.
Published: (2023)

CYP2D6 gene polymorphism and apatinib affect the metabolic profile of fluvoxamine
by: Zhize Ye, et al.
Published: (2022)

Safety and Feasibility of Low-Dose Apatinib Combined with S-1 as the Second-Line Therapy or Beyond in Chinese Patients with Pulmonary and Hepatic Metastasis of Nasopharyngeal Carcinoma
by: Zhou L, et al.
Published: (2020)

Mechanism of sorafenib resistance associated with ferroptosis in HCC
by: Lingling Guo, et al.
Published: (2023)

Effects of Apatinib on the Pharmacokinetics of Nifedipine and Warfarin in Patients with Advanced Solid Tumors
by: Zhu YT, et al.
Published: (2020)

The Safety and Efficacy of Camrelizumab and Its Combination With Apatinib in Various Solid Cancers
by: Kunlun Wang, et al.
Published: (2020)

The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China
by: Rui Meng, et al.
Published: (2022)

Population Pharmacokinetic Modelling and Simulation to Determine the Optimal Dose of Nanoparticulated Sorafenib to the Reference Sorafenib
by: Ki-Young Huh, et al.
Published: (2021)

Apatinib-loaded CalliSpheres Beads for embolization in a rabbit VX2 liver tumor: characterization in vitro, pharmacokinetics and tumor response in vivo
by: Qin Shi, et al.
Published: (2020)

TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure
by: Jin Lei, et al.
Published: (2022)

Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours
by: Guohui Liu, et al.
Published: (2019)

Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
by: Bo Shi, et al.
Published: (2022)

"Highly Exposed Chinese Herbal Medicine" Combined With Apatinib as Maintenance Treatment Following First-Line or Second-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Single-Arm, Prospective Study
by: Mingqi Wang, et al.
Published: (2021)

Thymoquinone, piperine, and sorafenib combinations attenuate liver and breast cancers progression: epigenetic and molecular docking approaches
by: Ashraf A. El-Shehawy, et al.
Published: (2023)

Sorafenib/2800Z Co-Loaded into Cholesterol and PEG Grafted Polylysine NPs for Liver Cancer Treatment
by: Chen Zhang, et al.
Published: (2023)

Improving anti-tumor activity of sorafenib tosylate by lipid- and polymer-coated nanomatrix
by: Yang Guo, et al.
Published: (2017)

The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer
by: Hong Zhao, et al.
Published: (2020)

Application of physiologically-based pharmacokinetic/pharmacodynamic models to evaluate the interaction between nifedipine and apatinib
by: Hongrui Liu, et al.
Published: (2022)

Sorafenib and sunitinib: A dermatologist's perspective
by: Vijendran Pragasam, et al.
Published: (2014)

Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib
by: Koen G. A. M. Hussaarts, et al.
Published: (2020)

Sorafenib-loaded hydroxyethyl starch-TG100-115 micelles for the treatment of liver cancer based on synergistic treatment
by: Guofei Li, et al.
Published: (2019)

Microvascular rarefaction caused by the NOTCH signaling pathway is a key cause of TKI-apatinib-induced hypertension and cardiac damage
by: WenJuan Wang, et al.
Published: (2024)

Sorafenib and Piperine co-loaded PLGA nanoparticles: Development, characterization, and anti-cancer activity against hepatocellular carcinoma cell line
by: Sulaiman S. Alhudaithi, et al.
Published: (2024)

Baicalin Enhanced Oral Bioavailability of Sorafenib in Rats by Inducing Intestine Absorption
by: Jingyao Wei, et al.
Published: (2021)

Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study
by: Zhuangzhuang Zheng, et al.
Published: (2022)